But even if LDL-C levels can now be starkly reduced in almost all patients with FH by combining statins, ezetimibe, PCSK9 inhibitors, and eventually apheresis, one hurdle still remains for patients with FH who concomitantly display elevated Lp(a) levels. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.